Imexpharm Corporation (HOSE:IMP)

Vietnam flag Vietnam · Delayed Price · Currency is VND
47,500
-850 (-1.76%)
At close: Apr 28, 2026
10.72%
Market Cap 7.32T
Revenue (ttm) 2.39T
Net Income (ttm) 311.12B
Shares Out 154.01M
EPS (ttm) 2,020.16
PE Ratio 23.51
Forward PE 19.92
Dividend 500.00 (1.03%)
Ex-Dividend Date Jun 9, 2025
Volume 18,623
Average Volume 44,465
Open 47,000
Previous Close 48,350
Day's Range 47,000 - 47,950
52-Week Range 42,600 - 57,000
Beta 0.61
RSI 16.63
Earnings Date Jul 17, 2026

About Imexpharm

Imexpharm Corporation operates as a pharmaceutical company in Vietnam. The company’s products include injectable antibiotics, oral antibiotics, cardiovascular, ophthalmology, musculoskeletal system, analgesic - anti-inflammatory - antipyretics, respiratory system, antihistamines and anti-allergy, central nervous system, digestive system, diabetes, anti-parasitic, external drugs, vitamins and minerals, and supplements. It is also involved in the import and export. Imexpharm Corporation was founded in 1997 and is headquartered in Cao Lãnh, Vietna... [Read more]

Industry Pharmaceutical Preparations
Founded 1997
Employees 1,444
Stock Exchange Ho Chi Minh Stock Exchange
Ticker Symbol IMP
Full Company Profile

Financial Performance

In 2025, Imexpharm's revenue was 2.44 trillion, an increase of 10.70% compared to the previous year's 2.21 trillion. Earnings were 304.39 billion, an increase of 10.34%.

Financial Statements

News

There is no news available yet.